Back to search
FDAFDA · Food and drugs·Recall number D-0100-2024

4.2% Sodium Bicarbonate Injection, USP 5 mEq/10 mL (0.5mEq/mL), Glass ABBOJECT Unit of Use Syringe, packaged as 1 vial and injector per carton, Rx only, Hospira Inc., Lake Forest, IL 60045, NDC 0409-5534-24

Published November 15, 2023 · Recall initiated: October 2, 2023

Summary

FDA records drug Class I recall D-0100-2024, published November 15, 2023 and initiated October 2, 2023. Recalling firm: Pfizer Inc.; Status: Terminated; Reported quantity: 24,900 vials; Lot: Lot#: GJ5007, Exp. 8/1/2024. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Presence of Particulate Matter: identified as glass.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Pfizer Inc.
Distributor
Nationwide in the US and Puerto Rico. The products were not distributed to government accounts or foreign consignees.
Lot
Lot#: GJ5007, Exp. 8/1/2024
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was 4.2% Sodium Bicarbonate Injection, USP 5 mEq/10 mL (0.5mEq/mL), Glass ABBOJECT Unit of Use Syringe, packaged as 1 vial and injector per carton, Rx only, Hospira Inc., Lake Forest, IL 60045, NDC 0409-5534-24 recalled?

Yes. FDA published recall D-0100-2024 on November 15, 2023. Reported hazard: Presence of Particulate Matter: identified as glass.

What should I do if I have this product?

Voluntary: Firm initiated · Letter